Detalles de la búsqueda
1.
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Expert Opin Drug Deliv
; 20(6): 863-870, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37273189
2.
A parametric model fitting time to first event for overdispersed data: application to time to relapse in multiple sclerosis.
Lifetime Data Anal
; 18(2): 139-56, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22083507
3.
Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies.
Ann Rheum Dis
; 69(9): 1687-90, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19640853
4.
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab.
Arch Dermatol Res
; 298(7): 329-38, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17021768
5.
Evaluation of efalizumab using safe psoriasis control.
BMC Dermatol
; 6: 8, 2006 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-16984639
6.
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
BMC Dermatol
; 5: 13, 2005 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-16359548
7.
Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment.
J Cutan Med Surg
; 9(6): 276-83, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16699900
Resultados
1 -
7
de 7
1
Próxima >
>>